Peptide Synthesis Service Market Size, Share Analysis, Key Companies, and Forecast To 2035

The peptide synthesis service market is estimated to be worth $1.7 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 13.6% during the forecast period.

Read More: https://www.rootsanalysis.com/....reports/peptide-ther

Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly. Presently, over 80 peptide-based drugs are available in the market for the treatment of an array of diseases, including cancer, chronic pain, diabetes, HIV infection, multiple sclerosis and osteoporosis. Further, since 2017, more than 10 peptide-based drugs have been approved by the USFDA. Of these, LupkynisTM and Zegalogue® were recently approved in 2021, while ImcivreeTM, Victoza®, LUPRON DEPOT®, Zoladex®, Sandostatin® and Somatuline® received approval in 2020.